Acrivon Therapeutics

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The AP3 platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients predicted to benefit from its drug candidates. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is being advanced in a potentially registrational Phase 2 trial across various tumor types. It is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Our mission is to develop groundbreaking drugs to treat unmet medical needs with an unwavering commitment to scientific excellence and patient care.

To be the gold standard in drug discovery and development and to positively impact the health of patients around the world.

Acrivon has been recognized with several industry awards for Innovation, Drug Discovery and Entrepreneurship, including the 2019 Neutrino Prize, the 2019 Tibbetts Awards, and the 2019 CBI BIO Innovation Award.